Suchergebnisse - "Subbiah, Vivek"

PubPharm (21)

1

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers : the RE-RAFFLE study

enthalten in: Molecular cancer | 2024

von Nelson, B. | Roszik, J. | Ahmed, J. | +11

2

Targeting All BRAF Alterations : The (Re)-Search Continues

enthalten in: JCO precision oncology | 2024

von Bhamidipati, D. | Pellatt, A. | Subbiah, V.

3

Expanding the Benefit : Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors

enthalten in: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting | 2023

von Gouda, M. | Subbiah, V.

4

Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer : A Single-Center Retrospective Cohort Study

enthalten in: Thyroid : official journal of the American Thyroid Association | 2023

von Zhao, X. | Wang, J. | Dadu, R. | +20

CommentIn: Thyroid. 2023 Apr;33(4):402-403. - PMID 36856459

5

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia

enthalten in: Blood | 2023

von Kreitman, R. | Moreau, P. | Ravandi, F. | +14

CommentIn: Blood. 2023 Mar 2;141(9):965-966. - PMID 36862436

6

Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors

enthalten in: JCO precision oncology | 2022

von Dankner, M. | Wang, Y. | Fazelzad, R. | +26

7

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors

enthalten in: Molecular cancer therapeutics | 2022

von Adashek, J. | Menta, A. | Reddy, N. | +3

8

Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer : Real-World Outcomes From Targeted and Standard Therapies

enthalten in: JCO precision oncology | 2021

von Hendifar, A. | Blais, E. | Wolpin, B. | +11

9

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply

enthalten in: The Lancet. Oncology | 2020

von Subbiah, V. | Lassen, U. | Gasal, E. | +2

CommentOn: Lancet Oncol. 2020 Sep;21(9):1234-1243. - PMID 32818466

10

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR) : a phase 2, open-label, single-arm, multicentre basket trial

enthalten in: The Lancet. Oncology | 2020

von Subbiah, V. | Lassen, U. | Élez, E. | +16

CommentIn: Lancet Oncol. 2020 Nov;21(11):e515. - PMID 33152306